Erythropoetin in Urologic Oncology

Albers, Peter; Heicappell, R.; Schwaibold, Hartwig; Wolff, J. M.

doi:10.1159/000052404

Cited by 21 publications

(9 citation statements)

References 63 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 Evidence that EPO has beneficial effects for urological organs first emerged when it was noted to protect testicular tissue after torsion and ischemic injury. 22 Based on the current findings we believe that pharmacological intervention using EPO to accelerate hydronephrosis resolution and promote normal ureteral peristalsis and urine flow after obstruction removal may decrease the risk of renal dysfunction and secondary infection due to the impaired urine flow associated with aperistalsis.…”

Section: Discussionmentioning

confidence: 99%

Erythropoietin Accelerates the Regeneration of Ureteral Function in a Murine Model of Obstructive Uropathy

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Erythropoietin Accelerates the Regeneration of Ureteral Function in a Murine Model of Obstructive Uropathy

et al. 2015

View full text Add to dashboard Cite

show abstract

“…[1245] Nearly 50% of these patients initially start off with preoperative anemia. [26] While ABT rates were demonstrated to be significantly higher in men over the age of 74 years, no such difference was seen in women in a study. [5] Age did not seem to be a factor in female patients, but, overall, females had higher transfusion rates than men.…”

Section: Discussionmentioning

confidence: 99%

Cost benefits of intraoperative cell salvage in radical cystectomy

Ubee¹,

Manikandan²,

Gudimetla³

et al. 2010

Indian J Urol

View full text Add to dashboard Cite

Objective:We have looked into the clinical and financial benefits of using intra-operative cell salvage (ICS) as a method to reduce the amount of autologous blood transfusion (ABT) requirement for our radical cystectomy (RC) patients.Materials and Methods:Fifteen consecutive patients undergoing radical cystectomy received cell salvaged blood (ICS), while 15 did not (NCS). The cost of using the cell saver, number of homologous transfusions, survival, and recurrences were recorded and compared using paired t-test and chi-square test between the two groups. A Dideco Electa® (Sorin Group, Electa, Italy) cell saver machine was used for all the patients in the ICS group and leukocyte filters were used on the salvaged blood before the autologous transfusion.Results:The mean age was 63 years (53–72 years), 66 years (46–79 years) in ICS and NCS groups, respectively (P = 0.368). All 15 (100%) patients in the NCS group required an allogenic transfusion compared to 9/15 (60%) in the ICS group (P = 0.08). There was a significant reduction in the mean volume of allogenic blood transfused with the use of cell saver. Median follow-up was 23 and 21 months in the ICS and NCS group with 10 and 4 patients alive at last follow-up, respectively. There was a saving of 355 pounds per patient in the ICS group compared to the NCS group.Conclusion:Our initial study shows that cell savage is feasible and safe in patients undergoing radical cystectomy. It does not adversely affect the medium term outcome of patients undergoing RC and is also cost effective.

show abstract

“…44 It has been suggested in the literature that in patients with prostate cancer, recombinant human erythropoietin use may be justified prior to radical prostatectomy to reduce autologous blood transfusion risk as well as in anemic patients with advanced, hormone-refractory disease. 45,46 However, in light of our findings, in patients with prostate cancer who may benefit from therapy with recombinant human erythropoietin, the expression of erythropoietin receptor in tumor cells may need to be taken into consideration in the design of future clinical trials. Erythropoietin exerts its cellular effects by binding to its specific transmembrane receptor, the erythropoietin receptor, a member of the Type I cytokine receptor superfamily, characterized by the absence of intrinsic tyrosine kinase enzymatic activity.…”

Section: Discussionmentioning

confidence: 99%

Erythropoietin and erythropoietin receptor expression in human prostate cancer

et al. 2005

View full text Add to dashboard Cite

Erythropoietin is a hematopoietic cytokine that regulates the production of red blood cells. Erythropoietin is normally produced in the adult kidney in a hypoxia-inducible manner. The recombinant form of human erythropoietin is in clinical use for the prevention and treatment of anemia that is associated with cancer and its treatment with chemoradiation therapy. A series of recent studies from our laboratory and others have reported the expression of receptors for erythropoietin in several different types of human cancer cells. In the present study, we investigated the expression of erythropoietin receptor and its ligand erythropoietin in human prostate cancer. In clinical specimens of prostate cancer, we found abundant expression of erythropoietin receptor protein in all primary tumors examined using immunohistochemistry. Furthermore, we observed erythropoietin coexpression in prostate cancer cells by immunohistochemical analysis. To determine whether monolayer cultures of continuous cell lines derived from prostate cancer also express erythropoietin receptor and erythropoietin, we studied well-characterized hormone-responsive (LNCaP) and hormone-refractory (PC-3) prostate cancer cell lines. We performed reverse-transcription and polymerase chain reaction assays to detect erythropoietin receptor and erythropoietin mRNA transcripts, and also immunoprecipitation and immunoblotting to detect erythropoietin receptor protein expression in prostate cancer cells. These experiments revealed the expression of both erythropoietin receptor and erythropoietin in LNCaP and PC-3 cells suggesting that these prostate cancer cell lines may serve as useful experimental models for further studies of erythropoietin and erythropoietin receptor function in prostate cancer. The coexpression of erythropoietin receptor and its ligand erythropoietin in human prostate cancer cells suggests the potential for growth regulation by erythropoietin-erythropoietin receptor in an autocrine or paracrine manner.

show abstract

Erythropoetin in Urologic Oncology

Cited by 21 publications

References 63 publications

Erythropoietin Accelerates the Regeneration of Ureteral Function in a Murine Model of Obstructive Uropathy

Erythropoietin Accelerates the Regeneration of Ureteral Function in a Murine Model of Obstructive Uropathy

Cost benefits of intraoperative cell salvage in radical cystectomy

Erythropoietin and erythropoietin receptor expression in human prostate cancer

Contact Info

Product

Resources

About